Our commercial applications derived from our core technologies are at the basis of our protein technologies business segment products and services offering and represent a solid foundation upon which we are successfully building our growing and recurring revenues generation business model. Our strategy in relation to our protein technologies business segment has been well defined; applying ProMetic's proprietary technologies to new and existing markets for large-scale drug purification, drug development, proteomics (the study of proteins) and the elimination of pathogens.
Our bioseparation technologies are used in a variety of applications for the production and purification of biopharmaceuticals, for the capture and removal of biocontaminants or to extract and recover valuable proteins from various sources. This is a process commonly known as “affinity chromatography”. This process is mainly used for the separation and isolation of proteins. The technique relies upon the ability of proteins to recognize and bind to target biomolecules (ligands) in a specific and reversible manner.
Our proprietary affinity adsorbents are manufactured in our UK based subsidiary (Isle of Man), ProMetic BioSciences Ltd (“PBL”). They are sold to and used by some of the most reputable biopharmaceutical companies in the world in their respective drugs manufacturing processes. Through years of research and development, PBL has built an extensive ligand library and now offers ligands targeting a vast selection of proteins.
PLASMA PROTEIN PURIFICATION SYSTEM (PPPSTM)
ProMetic exploits a proprietary platform derived from the use of PBL's affinity technology. ProMetic BioTherapeutics Inc., is responsible for the development and commercialization of the plasma purification process designated as Plasma Protein Purification System ("PPPSTM"). PPPSTM is a multi product sequential purification process originally developed in collaboration with the American Red Cross. It employs powerful affinity separation materials in a multi-step process to extract and purify commercially valuable plasma proteins in high yield. It allows for a highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best in class biotherapeutic products.